Tag Archives: BOLD

Audentes Therapeutics (BOLD) Gets a Buy Rating from Chardan Capital

In a report released today, Gbola Amusa from Chardan Capital reiterated a Buy rating on Audentes Therapeutics (BOLD – Research Report), with a price target of $50.00. The company’s shares closed last Monday at $27.84. According to TipRanks.com, Amusa is

Audentes Therapeutics (BOLD) Receives a Buy from Chardan Capital

In a report released yesterday, Gbola Amusa from Chardan Capital reiterated a Buy rating on Audentes Therapeutics (BOLD – Research Report), with a price target of $50. The company’s shares closed last Monday at $31.10. According to TipRanks.com, Amusa is

Analysts Offer Insights on Healthcare Companies: Audentes Therapeutics (NASDAQ: BOLD) and Rexahn Pharma (NASDAQ: REXN)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Audentes Therapeutics (BOLD – Research Report) and Rexahn Pharma (REXN – Research Report). Audentes Therapeutics (BOLD) Mizuho Securities analyst Difei Yang reiterated a

William Blair Keeps Their Hold Rating on Audentes Therapeutics (BOLD)

William Blair analyst Raju Prasad maintained a Hold rating on Audentes Therapeutics (BOLD – Research Report) yesterday. The company’s shares closed yesterday at $37.03. According to TipRanks.com, Prasad is a 4-star analyst with an average return of 13.6% and a

Audentes Therapeutics (BOLD) Received its Third Buy in a Row

After Wedbush and Mizuho Securities gave Audentes Therapeutics (NASDAQ: BOLD) a Buy rating last month, the company received another Buy, this time from Cowen & Co. Analyst Ritu Baral maintained a Buy rating on Audentes Therapeutics today. The company’s shares

Analysts Offer Insights on Healthcare Companies: Audentes Therapeutics (NASDAQ: BOLD) and Constellation Pharmaceuticals Inc (NASDAQ: CNST)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Audentes Therapeutics (BOLD – Research Report) and Constellation Pharmaceuticals Inc (CNST – Research Report) with bullish sentiments. Audentes Therapeutics (BOLD) In a